In multiple myeloma cell lines, the pan-HDACi panobinostat has demonstrated the capacity to markedly upregulate PD-L1 by enhancing STAT1 expression in the presence of IFN-γ [60], while the HDAC6-selective inhibitor A452 was shown to induce PD-L1 upregulation in multiple myeloma cells in vitro [61]. The gene discussed is HDAC6; the disease is plasma cell myeloma.